{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:22:10Z","timestamp":1791843730354,"version":"4.3.4"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009045","name":"Uniwersytet Jagiello\u0144ski Collegium Medicum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009045","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.msard.2025.106263","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T08:28:56Z","timestamp":1736238536000},"page":"106263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Efficacy and safety of disease-modifying therapies in pediatric-onset multiple sclerosis: A systematic review of clinical trials and observational studies"],"prefix":"10.1016","volume":"94","author":[{"given":"Katarzyna","family":"\u015aladowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Mo\u0107ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Brzostek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Kawalec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106263_bib0001","doi-asserted-by":"crossref","first-page":"e1008","DOI":"10.1212\/NXI.0000000000001008","article-title":"Use of disease-modifying therapies in pediatric relapsing-remitting multiple sclerosis in the United Kingdom","volume":"8","author":"Abdel-Mannan","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2025.106263_bib0002","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12883-018-1026-3","article-title":"Pediatric multiple sclerosis: a review","volume":"18","author":"Alroughani","year":"2018","journal-title":"BMC. Neurol."},{"key":"10.1016\/j.msard.2025.106263_bib0003","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1001\/archneur.58.10.1602","article-title":"Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years","volume":"58","author":"Amato","year":"2001","journal-title":"Arch. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106263_bib0004","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/jnnp-2019-322138","article-title":"Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study","volume":"91","author":"Arnold","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.msard.2025.106263_bib0005","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S1474-4422(07)70242-9","article-title":"Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions","volume":"6","author":"Banwell","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106263_bib0006","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1212\/01.WNL.0000152896.35341.51","article-title":"The cognitive burden of multiple sclerosis in children","volume":"64","author":"Banwell","year":"2005","journal-title":"Neurology."},{"issue":"11","key":"10.1016\/j.msard.2025.106263_bib0007","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1007\/s10072-022-06211-8","article-title":"Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study","volume":"43","author":"Baroncini","year":"2022","journal-title":"Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2025.106263_bib0008","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1352458518754364","article-title":"Long-term follow-up of pediatric MS patients starting treatment with injectable frstline agents: a multicentre, Italian, retrospective, observational study","volume":"25","author":"Baroncini","year":"2019","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2025.106263_bib0009","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/1352458519829698","article-title":"Childhood multiple sclerosis is associated with reduced brain volumes at first clinical presentation and brain growth failure","volume":"2","author":"Bartels","year":"2019","journal-title":"Mult. Scler."},{"issue":"11","key":"10.1016\/j.msard.2025.106263_bib0010","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1177\/0883073812452784","article-title":"Pediatric multiple sclerosis","volume":"27","author":"Bigi","year":"2012","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.msard.2025.106263_bib0011","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1177\/1352458517713669","article-title":"Pediatric-Onset multiple sclerosis and other acquired demyelinating syndromes of the central nervous system in Denmark during 1977-2015: a nationwide population-based incidence study","volume":"24","author":"Boesen","year":"2018","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2025.106263_bib0012","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.59.7.1006","article-title":"University of British Columbia MS Clinic Neurologists. Early onset multiple sclerosis: a longitudinal study","volume":"59","author":"Boiko","year":"2002","journal-title":"Neurology."},{"issue":"6","key":"10.1016\/j.msard.2025.106263_bib0013","doi-asserted-by":"crossref","first-page":"508","DOI":"10.5603\/PJNNS.a2020.0069","article-title":"Paediatric multiple sclerosis \u2014 Current diagnosis and Treatment","volume":"54","author":"Brola","year":"2020","journal-title":"Neurol. Neurochir. Pol."},{"issue":"9","key":"10.1016\/j.msard.2025.106263_bib0014","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/brain\/awaa199","article-title":"Improved relapse recovery in paediatric compared to adult multiple sclerosis","volume":"143","author":"Chitnis","year":"2020","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.msard.2025.106263_bib0015","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1056\/NEJMoa1800149","article-title":"Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis","volume":"379","author":"Chitnis","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.msard.2025.106263_bib0016","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S1474-4422(21)00364-1","article-title":"Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial","volume":"20","author":"Chitnis","year":"2021","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.msard.2025.106263_bib0017","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1177\/13524585241242050","article-title":"Teriflunomide in pediatric patients with relapsing multiple sclerosis: open-label extension of TERIKIDS","volume":"30","author":"Chitnis","year":"2024","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2025.106263_bib0018","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/1352458508101933","article-title":"Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States","volume":"15","author":"Chitnis","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106263_bib0019","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1212\/WNL.0b013e318288694e","article-title":"International pediatric MS Study Group clinical trials Summit: meeting report","volume":"80","author":"Chitnis","year":"2013","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.msard.2025.106263_bib0020","first-page":"58","article-title":"Consistent control of disease activity with fingolimod versus IFN \u03b2-1a in pediatric-onset multiple sclerosis: further insights from PARADIGMS","volume":"91","author":"Deiva","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106263_bib0021","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00431-015-2588-3","article-title":"Epidemiology of multiple sclerosis in the pediatric population of Sardinia, Italy","volume":"175","author":"Dell'Avvento","year":"2016","journal-title":"Eur. J. Pediatr."},{"issue":"15","key":"10.1016\/j.msard.2025.106263_bib0022","doi-asserted-by":"crossref","first-page":"e1709","DOI":"10.1212\/WNL.0000000000007267","article-title":"Dynamic gray matter volume changes in pediatric multiple sclerosis: a 3.5 year MRI study","volume":"92","author":"De Meo","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106263_bib0023","unstructured":"European Medicines Agency, European network of paediatric research at the european medicines agency (Enpr-EMA) https:\/\/www.ema.europa.eu\/en\/partners-networks\/networks\/european-network-paediatric-research-european-medicines-agency-enpr-ema (assessed 1 July 2024)."},{"issue":"4","key":"10.1016\/j.msard.2025.106263_bib0024","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/biomedicines8040071","article-title":"Current advances in pediatric onset multiple sclerosis","volume":"8","author":"Fisher","year":"2020","journal-title":"Biomedicines."},{"issue":"4","key":"10.1016\/j.msard.2025.106263_bib0025","first-page":"1","article-title":"Interferon beta-1b in treatment-na\u00efve paediatric patients with relapsing\u2013remitting multiple sclerosis: two-year results from the BETAPAEDIC study","volume":"3","author":"G\u00e4artner","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2025.106263_bib0026","doi-asserted-by":"crossref","unstructured":"Ghezi A., Amato M.P., Edan G. et al. The introduction of new medications in pediatric multiple sclerosis: open issues and challenges. Mult. Scler.. 2021; 27(3): 479\u2013482, doi: 10.1177\/1352458520930620.","DOI":"10.1177\/1352458520930620"},{"issue":"Suppl 4","key":"10.1016\/j.msard.2025.106263_bib0027","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1007\/s10072-005-0512-8","article-title":"Immunomodulatory Treatment of Early Onset MS (ITEMS) Group. Immunomodulatory Treatment of Early Onset MS (ITEMS) Group. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study","volume":"26","author":"Ghezzi","year":"2005","journal-title":"Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2025.106263_bib0028","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10072-009-0083-1","article-title":"Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience","volume":"30","author":"Ghezzi","year":"2009","journal-title":"Neurol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2025.106263_bib0029","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1191\/1352458505ms1206oa","article-title":"Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study","volume":"11","author":"Ghezzi","year":"2005","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2025.106263_bib0030","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10072-007-0804-2","article-title":"Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results","volume":"28","author":"Ghezzi","year":"2007","journal-title":"Neurol. Sci."},{"issue":"2","key":"10.1016\/j.msard.2025.106263_bib0031","first-page":"S97","article-title":"Pediatric multiple sclerosis: conventional first-line treatment and general management","volume":"87","author":"Ghezzi","year":"2016","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106263_bib0032","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1177\/1352458510375568","article-title":"The management of multiple sclerosis in children: a European view","volume":"16","author":"Ghezzi","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106263_bib0033","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12883-015-0433-y","article-title":"Natalizumab in the pediatric MS population: results of the Italian registry","volume":"15","author":"Ghezzi","year":"2015","journal-title":"BMC. Neurol."},{"key":"10.1016\/j.msard.2025.106263_bib0034","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/1352458512471878","article-title":"Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases","volume":"19","author":"Ghezzi","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106263_bib0035","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/1352458512471878","article-title":"Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases","volume":"19","author":"Ghezzi","year":"2013","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.msard.2025.106263_bib0036","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1212\/WNL.0b013e3181f11daf","article-title":"Safety and efficacy of natalizumab in children with multiple sclerosis","volume":"75","author":"Ghezzi","year":"2010","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.msard.2025.106263_bib0037","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40120-020-00212-5","article-title":"A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis","volume":"9","author":"Giovannoni","year":"2020","journal-title":"Neurol. Ther."},{"issue":"8","key":"10.1016\/j.msard.2025.106263_bib0038","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00210-022-02238-y","article-title":"Natalizumab therapy in patients with pediatric onset multiple sclerosis in Greece: clinical and immunological insights of time long administration and future directions\u2014A single center retrospective observational study","volume":"395","author":"Gontika","year":"2022","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"issue":"1","key":"10.1016\/j.msard.2025.106263_bib0039","article-title":"Increased relapse rate in paediatric-onset compared with adult-onset multiple sclerosis","volume":"66","author":"Gorman","year":"2009","journal-title":"Arch Neurol [Internet]"},{"issue":"2","key":"10.1016\/j.msard.2025.106263_bib0040","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/jnnp-2012-303996","article-title":"Long-term outcome of paediatric onset multiple sclerosis: a population based study","volume":"84","author":"Harding","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106263_bib0041","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"issue":"1","key":"10.1016\/j.msard.2025.106263_bib0042","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1352458517732843","article-title":"Therapy of highly active pediatric multiple sclerosis","volume":"25","author":"Huppke","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"issue":"1","key":"10.1016\/j.msard.2025.106263_bib0043","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/vaccines9010012","article-title":"Safety of newer disease modifying therapies in multiple sclerosis","volume":"9","author":"Jalkh","year":"2021","journal-title":"Vaccines. (Basel)"},{"key":"10.1016\/j.msard.2025.106263_bib0044","doi-asserted-by":"crossref","DOI":"10.21037\/pm-21-90","article-title":"Necessity and limitations of paediatric research\u2014A personal view","volume":"6","author":"Korinthenberg","year":"2023","journal-title":"Pediatr. Med."},{"issue":"1","key":"10.1016\/j.msard.2025.106263_bib0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2021-000215","article-title":"Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study","volume":"4","author":"Krupp","year":"2022","journal-title":"BMJ Neurol. Open"},{"issue":"1","key":"10.1016\/j.msard.2025.106263_bib0046","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25737","article-title":"US Network of Pediatric MS Centers. Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis","volume":"88","author":"Krysko","year":"2020","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106263_bib0047","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/13524585221144742","article-title":"Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: a post hoc analysis of the randomized TERIKIDS trial","volume":"29","author":"Kuhle","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106263_bib0048","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.0b013e31822facdd","article-title":"Incidence of acquired CNS demyelinating. syndromes in a multiethnic cohort of children","volume":"77","author":"Langer-Gould","year":"2011","journal-title":"Neurology."},{"issue":"11","key":"10.1016\/j.msard.2025.106263_bib0049","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1136\/archdischild-2015-310001","article-title":"Informed consent for paediatric clinical trials in Europe","volume":"101","author":"Lepola","year":"2016","journal-title":"Arch. Dis. Child"},{"issue":"12","key":"10.1016\/j.msard.2025.106263_bib0050","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s00415-019-09395-w","article-title":"Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"267","author":"Li","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106263_bib0051","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1212\/01.wnl.0000259420.54635.63","article-title":"The psychosocial consequences of pediatric multiple sclerosis","volume":"68","author":"MacAllister","year":"2007","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106263_bib0052","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res. Synth. Methods"},{"issue":"9","key":"10.1016\/j.msard.2025.106263_bib0053","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamaneurol.2019.1546","article-title":"Long-term cognitive outcomes in patients with pediatric-onset vs adult-onset multiple sclerosis","volume":"76","author":"McKay","year":"2019","journal-title":"JAMa Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106263_bib0054","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jpeds.2003.10.056","article-title":"KIDMUS Study Group. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability","volume":"144","author":"Mikaeloff","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.msard.2025.106263_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105647","article-title":"Clinical and magnetic resonance imaging outcomes in pediatric-onset MS patients on fingolimod and okrelizumab","volume":"87","author":"Nasr","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106263_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105647","article-title":"Clinical and magnetic resonance imaging outcomes in pediatric-onset MS patients on fingolimod and ocrelizumab","volume":"87","author":"Nasr","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106263_bib0057","unstructured":"National Library of Medicine, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02137109 (assessed 1 July 2024i)."},{"key":"10.1016\/j.msard.2025.106263_bib0058","unstructured":"National Library of Medicine, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03087136 (assessed 1 July 2024h)."},{"key":"10.1016\/j.msard.2025.106263_bib0059","unstructured":"National Library of Medicine, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03368664 (assessed 1 July 2024g)."},{"key":"10.1016\/j.msard.2025.106263_bib0060","unstructured":"National Library of Medicine, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04667949 (assessed 1 July 2024f)."},{"key":"10.1016\/j.msard.2025.106263_bib0061","unstructured":"National Library of Medicine, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04926818 (assessed 1 July 2024e)."},{"key":"10.1016\/j.msard.2025.106263_bib0062","unstructured":"National Library of Medicine, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT01892722 (assessed 1 July 2024d)."},{"key":"10.1016\/j.msard.2025.106263_bib0063","unstructured":"National Library of Medicine, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05123703 (assessed 1 July 2024c)."},{"key":"10.1016\/j.msard.2025.106263_bib0064","unstructured":"National Library of Medicine, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03958877 (assessed 1 July 2024b)."},{"key":"10.1016\/j.msard.2025.106263_bib0065","unstructured":"National Library of Medicine, ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06408259 (assessed 1 July 2024a)."},{"issue":"8","key":"10.1016\/j.msard.2025.106263_bib0066","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1212\/WNL.0000000000001856","article-title":"Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis","volume":"85","author":"Novotna","year":"2015","journal-title":"Neurology."},{"issue":"11","key":"10.1016\/j.msard.2025.106263_bib0067","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11910-018-0886-7","article-title":"Pediatric multiple sclerosis: an update","volume":"18","author":"Otallah","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.msard.2025.106263_bib0068","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.msard.2025.106263_bib0069","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1055\/s-2006-924723","article-title":"Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a","volume":"37","author":"Pakdaman","year":"2006","journal-title":"Neuropediatrics."},{"key":"10.1016\/j.msard.2025.106263_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102865","article-title":"TyPed study: natalizumab for the treatment of pediatric-onset multiple sclerosis in Portugal","volume":"51","author":"Palavra","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106263_bib0071","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1212\/01.WNL.0000153570.33845.6A","article-title":"Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a","volume":"64","author":"Pohl","year":"2005","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106263_bib0072","doi-asserted-by":"crossref","DOI":"10.1212\/01.wnl.0000259407.40023.ab","article-title":"Treatment of pediatric multiple sclerosis and variants","volume":"68","author":"Pohl","year":"2007","journal-title":"Neurology."},{"issue":"9","key":"10.1016\/j.msard.2025.106263_bib0073","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3390\/v13091684","article-title":"Risk assessment of progressive multifocal leukoencephalopathy in multiple sclerosis patients during 1 year of ocrelizumab treatment","volume":"13","author":"Prezioso","year":"2021","journal-title":"Viruses."},{"key":"10.1016\/j.msard.2025.106263_bib0074","unstructured":"PROSPERO database https:\/\/www.crd.york.ac.uk\/prospero\/ Accessed July 2024."},{"key":"10.1016\/j.msard.2025.106263_bib0075","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1212\/WNL.41.5.685","article-title":"Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction","volume":"41","author":"Rao","year":"1991","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106263_bib0076","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/ene.12371","article-title":"Multiple sclerosis in children and adolescents: incidence and clinical picture - new insights from the nationwide German surveillance (2009-2011)","volume":"21","author":"Reinhardt","year":"2014","journal-title":"Eur. J. Neurol."},{"issue":"25","key":"10.1016\/j.msard.2025.106263_bib0077","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa067597","article-title":"Adult neurology departments KIDMUS study group. natural history of multiple sclerosis with childhood onset","volume":"356","author":"Renoux","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.msard.2025.106263_bib0078","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/glia.23624","article-title":"Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination","volume":"67","author":"Rivera","year":"2019","journal-title":"Glia"},{"key":"10.1016\/j.msard.2025.106263_bib0079","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/archdischild-2011-300286","article-title":"A european network of paediatric research at the european medicines agency (Enpr-EMA)","volume":"97","author":"Ruperto","year":"2012","journal-title":"Arch. Dis. Childh."},{"issue":"7","key":"10.1016\/j.msard.2025.106263_bib0080","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2023-0016","article-title":"Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis","volume":"12","author":"Samjoo","year":"2023","journal-title":"J. Comp. Eff. Res."},{"issue":"6","key":"10.1016\/j.msard.2025.106263_bib0081","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2217\/cer-2020-0267","article-title":"Efficacy classification of modern therapies in multiple sclerosis","volume":"10","author":"Samjoo","year":"2021","journal-title":"J. Comp. Eff. Res."},{"key":"10.1016\/j.msard.2025.106263_bib0082","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejpn.2023.05.001","article-title":"Treatments of pediatric multiple sclerosis: efficacy and tolerance in a longitudinal follow-up study","volume":"5","author":"Saponaro","year":"2023","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106263_bib0083","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","article-title":"Association of British Neutrologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis","volume":"15","author":"Scolding","year":"2015","journal-title":"Pract. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2025.106263_bib0084","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11940-021-00677-1","article-title":"Early aggressive treatment approaches for multiple sclerosis","volume":"23","author":"Simpson","year":"2021","journal-title":"Curr. Treat. Options. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2025.106263_bib0085","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1007\/s10072-022-06197-3","article-title":"Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"43","author":"\u015aladowska","year":"2022","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106263_bib0086","first-page":"1","article-title":"The state and future of pediatric research-an introductory overview","volume":"24","author":"Speer","year":"2023","journal-title":"Pediatr. Res."},{"issue":"66","key":"10.1016\/j.msard.2025.106263_bib0087","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"3","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.msard.2025.106263_bib0088","doi-asserted-by":"crossref","first-page":"8251","DOI":"10.3390\/ijms24098251","article-title":"The state of the art of pediatric multiple sclerosis","volume":"24","author":"Telenau","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.msard.2025.106263_bib0089","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/0883073813488828","article-title":"Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective study","volume":"28","author":"Tenembaum","year":"2013","journal-title":"J. Child Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106263_bib0090","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40263-017-0412-5","article-title":"Outcome measures in clinical trials for multiple sclerosis","volume":"31","author":"van Munster","year":"2017","journal-title":"CNS. Drugs"},{"issue":"9","key":"10.1016\/j.msard.2025.106263_bib0091","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.30439","article-title":"Effect of dimethyl fumarate vs interferon \u03b2-1a in patients with pediatric-onset multiple sclerosis: the CONNECT randomized clinical trial","volume":"5","author":"Vermersch","year":"2022","journal-title":"JAMa Netw. Open."},{"issue":"14","key":"10.1016\/j.msard.2025.106263_bib0092","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1177\/1352458519891984","article-title":"Cognitive processing speed in pediatric-onset multiple sclerosis: baseline characteristics of impairment and prediction of decline","volume":"26","author":"Wallach","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106263_bib0093","doi-asserted-by":"crossref","first-page":"e2538","DOI":"10.1212\/WNL.0000000000007572","article-title":"Clinical trials of disease-modifying agents in pediatric MS: opportunities, challenges, and recommendations from the IPMSSG","volume":"92","author":"Waubant","year":"2019","journal-title":"Neurology."},{"issue":"8","key":"10.1016\/j.msard.2025.106263_bib0094","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/archneurol.2009.135","article-title":"Difference in disease burden and activity in paediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults","volume":"66","author":"Waubant","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2025.106263_bib0095","unstructured":"Wells G.A., Shea B., O'Connell et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp (assessed 1 July 2024)."},{"issue":"5","key":"10.1016\/j.msard.2025.106263_bib0096","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/1352458520926869","article-title":"Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program","volume":"27","author":"Wiendl","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106263_bib0097","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102260","article-title":"Epidemiology of pediatric multiple sclerosis: a systematic literature review and meta-analysis","volume":"44","author":"Yan","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2025.106263_bib0098","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archneurol.2010.325","article-title":"Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis","volume":"68","author":"Yeh","year":"2011","journal-title":"Arch. Neurol."},{"issue":"Pt 12","key":"10.1016\/j.msard.2025.106263_bib0099","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1093\/brain\/awp278","article-title":"Magnetic resonance imaging characteristics of children and adults with paediatriconset multiple sclerosis","volume":"132","author":"Yeh","year":"2009","journal-title":"Brain"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T11:39:07Z","timestamp":1740310747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825000070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":99,"alternative-id":["S2211034825000070"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106263","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of disease-modifying therapies in pediatric-onset multiple sclerosis: A systematic review of clinical trials and observational studies","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106263"}}